Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | RGS4 | P49798 | 1/20 | 0.54 |
| ▸ | RGS8 | P57771 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891433 | 1.00 | CASP3 (0.58) | CASP3P2RX4CMA1RGS4RGS8 | |
| SCHEMBL5875112 | 0.86 | ELANE (0.55) | CASP3P2RX4CMA1RGS4KDM4E | |
| SCHEMBL5891372 | 0.81 | GAA (0.50) | KDM4EGAASMN1; SMN2POLBPIM1 | |
| SCHEMBL45154 | 0.79 | CASP3 (0.88) | CASP3CMA1KDM4EGAAMEN1 | |
| SCHEMBL30296449 | 0.79 | CASP3 (0.88) | CASP3CMA1KDM4EGAAMEN1 | |
| SCHEMBL28080906 | 0.78 | NR1H2 (0.71) | CASP3CMA1KDM4EEP300NR1H2 | |
| SCHEMBL30320663 | 0.78 | NR1H2 (0.71) | CASP3CMA1KDM4EEP300NR1H2 | |
| SCHEMBL320830 | 0.76 | RGS4 (0.53) | P2RX4CMA1RGS4RGS8KDM4E | |
| SCHEMBL11257792 | 0.75 | MEN1 (0.64) | P2RX4GAASMN1; SMN2POLBMAPK1 | |
| SCHEMBL8331785 | 0.75 | CMA1 (0.70) | CASP3CMA1KDM4EGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071355-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-07-04 | — | — | US | claimed |
| JP-2006511564-A | — | — | 2006-04-06 | — | — | JP | claimed |
| EP-1581477-A1 | CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2005-10-05 | — | — | EP | claimed |
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2004-09-09 | — | — | US | claimed |
| WO-2004056746-A1 | CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-07-08 | — | — | WO | claimed |
| US-7071355-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | MSR1, PPARG, PPARA | CASP3 2182/4885P2RX4 555/4885CMA1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.